Singapore markets closed

Straits Times Index
3,136.86
+20.54(+0.66%)
S&P 500
4,591.67
+53.24(+1.17%)
Dow
35,227.03
+646.95(+1.87%)
Nasdaq
15,225.15
+139.68(+0.93%)
BTC-USD
51,343.61
+3,263.20(+6.79%)
CMC Crypto 200
1,328.31
+68.15(+5.41%)

AIRLINES

Omicron’s rapid spread shreds budding recovery in air travel

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

4.2900

+0.1200

(+2.88%)

At close: 04:00PM EST

4.2200

-0.07

(-1.63%)

After hours:

05:42PM EST

Loading interactive chart…

Zacks
MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.